Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

estradiol, norethindrone drug combination 9elagolix 7Estradiol 7asoprisnil 6relugolix 5Norethindrone Acetate 5vilaprisan 4Uterine Myomectomy 4Uterine Artery Embolization 4linzagolix 2ulipristal acetate 1ulipristal 1pycnogenols 1Tranexamic Acid 1Radiofrequency Ablation 1Progesterone 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Ibuprofen 1Hysterectomy 1Endomet 1Electrocoagulation 1Cryosurgery 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Menorrhagia × Medroxyprogesterone Acetate × Clear all
NCT06671548 2026-02-02

Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
120 enrolled

Leiomyoma, Menorrhagia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡